News

Piramal Pharma announced that USFDA has issued an Establishment Inspection Report (EIR) for the company`s manufacturing facility located at Sellersville (USA) and the inspection has now been successfully closed by USFDA.

Piramal Pharma announced that the Annual General Meeting(AGM) of the company will be held on 30 July 2026.

Piramal Pharma has allotted 21 lakh equity shares under ESOP on 05 June 2026. Consequently, the paid up equity share capital has increased to Rs. 1,331,34,81,300 (consisting of 133,13,48,130 equity shares of face value of Rs. 10/- each).

Net loss of Piramal Pharma reported to Rs 8.83 crore in the quarter ended March 2026 as against net profit of Rs 153.50 crore during the previous quarter ended March 2025. Sales declined 0.08% to Rs 2751.77 crore in the quarter ended March 2026 as against Rs 2754.07 crore during the previous quarter ended March 2025.For the full year,net loss reported to Rs 325.94 crore in the year ended March 2026 as against net profit of Rs 91.13 crore during the previous year ended March 2025. Sales declined 3.08% to Rs 8869.08 crore in the year ended March 2026 as against Rs 9151.18 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales2751.772754.07 0 8869.089151.18 -3 OPM %16.7420.37 -10.3915.79 - PBDT437.15515.56 -15 851.321230.98 -31 PBT218.77272.80 -20 20.08414.64 -95 NP-8.83153.50 PL -325.9491.13 PL Powered by Capital Market - Live News

Piramal Pharma will hold a meeting of the Board of Directors of the Company on 28 April 2026.